Mustang Bio, Inc., a Fortress Biotech company, is a biopharmaceutical company focused on the development of novel immunotherapies based on ground breaking Chimeric Antigen Receptor (CAR) research and gene therapies in areas of unmet need.
Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Mustang Bio Announces Presentation of MB-102 (CD123 CAR) Safety and Efficacy Data at AACR Special Conference on Tumor Immunology and Immunotherapy
Mustang Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
FOX & friends interview with Fortress Biotech and Mustang Bio